<DOC>
	<DOC>NCT01538862</DOC>
	<brief_summary>This is a feasibility study to see if Granulocyte Colony Stimulating Factor (GCSF) is effective as a treatment of Dystrophic Epidermolysis Bullosa (EB.) Patients will receive one course of treatment with the study drug. The course will be 7 days in length. After receiving GCSF, patients will be followed at 7 and 30 days following the discontinuation of the drug. Thirty day follow up can be done via telephone communication with the patient or family.</brief_summary>
	<brief_title>Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients With Dystrophic Epidermolysis Bullosa</brief_title>
	<detailed_description />
	<mesh_term>Epidermolysis Bullosa</mesh_term>
	<mesh_term>Epidermolysis Bullosa Dystrophica</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Each patient must have the diagnosis of severe generalized recessive dystrophic EB (formerly known as HallopeauSiemens RDEB) confirmed by clinical criteria and either of the following: 1. transmission electron microscopy 2. immunofluorescence antigenic mapping and type VII collagen monoclonal antibody staining 3. COL7A1 mutational analysis The patient must not have a history of squamous cell carcinoma or any internal malignancy. Female patients who are pregnant. Patients with active signs and symptoms of infection.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>